Role
ATAGI's role is to:
- advise the Minister for Health and Aged Care on the medical administration of vaccines available in Australia, including those available through the National Immunisation Program (NIP)
- provide advice to research organisations on current immunisation research and areas that need more research
- provide industry sponsors with pre-submission advice for potential submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) on vaccine effectiveness and use in Australia. ATAGI advice must be sought prior to a sponsor making a submission to the PBAC (see parallel processing requirements for PBAC vaccine submissions and pre-submission advice for industry sponsors wishing to make a PBAC submission)
- consult with relevant organisations to produce the Australian Immunisation Handbook
- consult with relevant organisations in implementing immunisation policies, procedures and vaccine safety.
For more detail, take a look at:
Members
From 1 July 2021, Professor Nigel Crawford took on the role of Chair, and Professor Michelle Giles took on the role of Deputy Chair of ATAGI.
From 1 January 2022, Professor Michelle Giles and Professor Katie Flanagan are the ATAGI COVID-19 Working Group co-leads.
Professor Allen Cheng and Professor Chris Blyth’s roles as co-Chairs of the ATAGI COVID-19 Working Group ceased on 31 December 2021.
A revised list reflecting the 2022 ATAGI COVID-19 Working Group structure is available.
Below are the ATAGI members as at 1 January 2022.
Voting members
| Name | Area of expertise | Position |
|---|---|---|
|
Prof Nigel Crawford |
Chair, Vaccine Safety, Special Risk Groups |
Director, Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC), Murdoch Children’s Research Institute Medical Head, Immunisation Services Royal Children’s Hospital, Melbourne Senior Fellow, Department of Paediatrics, University of Melbourne |
|
Prof Michelle Giles |
Deputy Chair, Infectious Disease Physician, Maternal Immunisation |
Director, Infections in Pregnancy service, Monash Infectious Diseases
Infectious Diseases Physician (Alfred Health, Monash Health, Royal Women’s Hospital, Sunshine Hospital) Adjunct Clinical Professor Department of Obstetrics and Gynaecology, Monash University Department of Infectious Diseases, Doherty Institute for Infection and Immunity |
|
Prof Allen Cheng |
Epidemiology, Public Health |
Infectious Disease Physician and Director, Infection Prevention Healthcare Epidemiology Unit, Alfred Health |
|
Ms Karen Bellamy |
Immunisation Nurse Practitioner |
Monash Health, South East Public Health Unit (SEPHU) |
|
Prof Katie Flanagan |
Infectious Diseases |
Head of Infectious Diseases, Launceston General Hospital Adjunct Professor, School of Medicine, University of Tasmania
Associate Professor, Dept of Immunology and Pathology, Monash University, Melbourne |
|
Dr Katherine Gibney |
Infectious Diseases and Public Health Physician, Epidemiology |
Infectious Diseases Physician, Victorian Infectious Diseases Service, The Royal Melbourne Hospital Senior Research Fellow, The Peter Doherty Institute for Infection and Immunity |
|
Dr Penelope Burns |
General Practitioner |
Clinical Associate Professor, Australian National University Conjoint Senior Lecturer Western Sydney University |
|
Prof Cheryl Jones |
Paediatrics |
Head of School and Dean, Sydney Medical School Faculty of Medicine and Health, University of Sydney
Honorary Consultant, Paediatric Infectious Diseases Sydney Children's Hospital Network |
|
Prof Tony Korman |
Infectious Diseases, Clinical Microbiology |
Director, Monash Infectious Diseases, Monash Health Director, Microbiology, Monash Health Adjunct Clinical Professor, Monash University |
|
A/Prof Bette Liu |
Epidemiology, Public Health |
Associate Professor and NHMRC Career Development Fellow, School of Population Health, UNSW Sydney Head, Population Health Group, National Centre for Immunisation Research and Surveillance |
|
Dr Nicholas Silberstein |
General Practitioner |
General Practitioner, Victoria |
|
Dr James Wood |
Infectious Diseases Epidemiology, Population Health |
Associate Professor, School of Public Health and Community Medicine, UNSW Sydney |
|
Ms Diane Walsh |
Consumer Health Issues |
Consumers Health Forum, Chair of Northern Territory, Primary Health Network |
|
Prof Tom Snelling |
Paediatrics and special risk groups |
Director of Health and Clinical Analysis, University of Sydney Infectious Diseases Physician, Sydney Children’s Hospital Foundation |
|
Ms Kristy Cooper |
Senior Nurse Practitioner |
Aboriginal, Torres Strait Islander Representative Primary Health Care / Family Nurse Practitioner Authorised Tasmanian Immunisation Provider Tasmanian Aboriginal Health Service |
Ex-officio members
| Name | Area of expertise | Position |
|---|---|---|
|
Mr Nicholas Stoney |
Representative from Department of Health and Aged Care |
Assistant Secretary, Immunisation Branch, Department of Health and Aged Care |
|
Yashwant Sinha |
Representative from the Therapeutic Goods Administration |
Office of Medicines Authorisation Market Authorisation Group, Therapeutic Goods Administration |
|
Prof Kristine Macartney |
National Centre for Immunisation Research and Surveillance (NCIRS) |
Director, National Centre for Immunisation Research and Surveillance Paediatrician and Infectious Diseases Specialist |
|
Ms Catherine Radkowksi |
National Immunisation Committee (NIC) |
Senior Technical Specialist, Health Protection Branch, Department of Health |
|
Dr Louise Flood |
Communicable Diseases Network Australia (CDNA) |
Director, Communicable Disease Control Branch, Department for Health and Wellbeing, South Australia |
|
Prof. Andrew Wilson |
Pharmaceutical Benefits Advisory Committee (PBAC) |
Chair - Pharmaceutical Benefits Advisory Committee |
|
Ms Jo Watson |
Pharmaceutical Benefits Advisory Committee (PBAC) |
Deputy Chair - Pharmaceutical Benefits Advisory Committee |
Membership guidelines
- ATAGI declaration of interest disclosures
- ATAGI declaration of interest procedures
- ATAGI policies and procedures, effective 1 July 2019
Statements
- ATAGI statement on the intradermal use of Imojev Japanese encephalitis vaccine
- ATAGI 2022 annual statement on immunisation
-
Statement on the clinical use of zoster vaccine in older adults in Australia
COVID-19 vaccination statements
- 15 November 2022 – ATAGI recommendations on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years
-
15 November 2022 – ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
- 24 October 2022 – ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years
-
23 September 2022 – updated guidance on myocarditis and pericarditis after COVID-19 vaccines
-
12 September 2022 – statement on use of the Moderna bivalent Original/Omicron vaccine
- 25 August 2022 – Novavax vaccine for adolescents aged 12-17 years
- 3 August 2022 – ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years
- 7 July 2022 – updated recommendations for a winter dose of the COVID-19 vaccine
- 9 June 2022 – on the use of a first booster dose in adolescents aged 12-15 years
- 25 May 2022 – expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
- 8 April 2022 – on use of booster doses in adolescents aged 12-15 years
- 6 April 2022 – advice on the use of sedation for COVID-19 vaccination
- 25 March 2022 – recommendations on a winter booster dose of COVID-19 vaccine
- 2 March 2022 – updated statement on the use of a booster dose of COVID-19 vaccine
- 23 February 2022 – recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years
- 10 February 2022 – statement on defining 'up-to-date' status for COVID-19 vaccination
- 3 February 2022 – recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years
- 24 January 2022 – statement on the use of the Novavax vaccine for those 18 years and older
- 24 January 2022 – guidance on temporary medical exemptions – reduced to 4 months after testing positive for COVID-19
- 17 January 2022 – recommendations for a third primary dose for people aged 5 years and older who are severely immunocompromised
- 24 December 2021 – statement on Omicron variant and the timing of COVID-19 booster vaccination
- 17 December 2021 – statement on Omicron variant
- 12 December 2021 – Omicron variant and timing of COVID-19 booster vaccination
- 12 December 2021 – recommendations on the use of Spikevax (Moderna) as a COVID-19 booster vaccine
- 10 December 2021 – response to ATAGI advice about vaccinating 5 to 11-year-olds against COVID-19
- 7 December 2021 – advice on the administration of seasonal influenza vaccines in 2021 (December 2021)
- 3 December 2021 – on SARS-CoV-2 Omicron variant and COVID-19 booster doses
- 28 October 2021 – recommendations on the use of a booster dose of COVID-19 vaccine
- 8 October 2021 – on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised
- 23 September 2021 – on the need for additional doses of COVID-19 vaccines
- 27 August 2021 – on the use of COVID-19 vaccines in all young adolescents in Australia
- 9 August 2021 – on considerations for establishing drive-through COVID-19 vaccination clinic sites
- 2 August 2021 – regarding COVID-19 vaccines in the setting of transmission of the Delta variant of concern
- 24 July 2021 – response to NSW COVID-19 outbreak 24th July 2021
- 13 July 2021 – on the use of COVID-19 vaccines in an outbreak setting
- 17 June 2021 – on revised recommendations on the use of COVID-19 Vaccine AstraZeneca
- 9 June 2021 – joint statement between RANZCOG and ATAGI about COVID-19 vaccination for pregnant women
- 23 May 2021 – joint statement on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca
- 23 April 2021 – on use of COVID-19 vaccines following review of vaccine safety data and benefits
- 8 April 2021 – on AstraZeneca vaccine in response to new vaccine safety concerns
- 2 April 2021 – on COVID-19 vaccination and a reported case of thrombosis
- 2 April 2021 – for consumers on a specific clotting condition being reported after COVID-19 vaccination
- 25 March 2021 – for health care providers on suitability of COVID-19 vaccination in people with history of clotting conditions
- 19 March 2021 – statement and clinical guidance on AstraZeneca COVID-19 vaccine following European Medicines Agency (EMA) safety review
- 16 March 2021 – in response to European decisions about the AstraZeneca vaccine
COVID-19 updates
-
15 November 2022 – update following COVID-19 meeting – 11 November
-
14 September 2022 – update following weekly COVID-19 meeting – 7 September
-
2 September 2022 – update following weekly COVID-19 meeting – 31 August 2022
-
26 August 2022 – update following weekly COVID-19 meeting – 24 August 2022
-
3 August 2022 – recommendations COVID-19 vaccine for children aged 6 months to under 5 years
-
27 July 2022 – ongoing review of COVID-19 vaccine for children aged 6 months to under 5 years and ongoing safety review of COVID-19 vaccines
-
20 July 2022 – update on WHO TAG-CO-VAC, impact of COVID-19 vaccination in children
-
13 July 2022 – Impact of COVID-19 vaccination in children, 4th dose reinfection interval and use in pregnancy
-
6 July 2022 – Update to the recommendations for a 4th (winter dose) of a COVID-19 vaccine
- 29 June 2022 – Update to the recommendations on Novavax COVID-19 boosters, review of additional booster (winter) doses, review of data on impact of COVID-19 on children
- 1 June 2022 – Update following weekly COVID-19 meeting
- 25 May 2022 – Expanded winter boosters and ongoing review of boosters for 12-15 year olds
- 23 May 2022 – Ongoing review of adverse events and safety information
- 11 May 2022 – Omicron vaccine effectiveness and ongoing review of COVID-19 booster
- 4 May 2022 – Ongoing review of COVID-19 booster and safety information
- 27 April 2022 – Updates to mRNA COVID-19 vaccine dose intervals, rates of myocarditis and pericarditis and timing of vaccination post infection
- 20 April 2022 – Recommendations on boosters for 12-15 year old adolescents
- 30 March 2022 – Resources on additional winter booster doses, use of sedation for COVID-19 vaccination
- 23 March 2022 – Recommendations on a winter booster dose of COVID-19 vaccine
- 16 March 2022 – Consideration of second COVID-19 booster doses
- 9 March 2022 – Evidence relating to second COVID-19 booster doses
- 2 March 2022 – Advice on booster vaccines
- 23 February 2022 – 6-11 Moderna, clinical guidance, medical exemptions for COVID-19 vaccines
- 16 February 2022 – RATs as proof of infection, 6-11 Moderna, Novavax booster
- 9 February 2022 – Defining ‘up-to-date’ status, duration of observation after COVID-19 vaccination
- 2 February 2022 – Boosters for adolescents aged 16-17 years
- 27 January 2022 – Vaccination post-infection
- 19 January 2022 – Vaccination post-infection, Novavax registration, dose interval in children aged 5 to 11 years
- 12 January 2022 – Dose intervals for vaccination of 5-11 year old children, safety update
- 22 December 2021
- 15 December 2021
- 8 December 2021
- 1 December 2021
- 24 November 2021
- 17 November 2021
- 10 November 2021
- 3 November 2021
- 27 October 2021
- 20 October 2021
- 13 October 2021
- 6 October 2021
- 29 September 2021
- 22 September 2021
- 15 September 2021
- 8 September 2021
- 1 September 2021
- 25 August 2021
- 19 August 2021
- 11 August 2021
- 4 August 2021
- 28 July 2021
- 21 July 2021
- 14 July 2021
- 7 July 2021
- 30 June 2021
- 23 June 2021
- 9 June 2021
- 2 June 2021
- 26 May 2021
- 19 May 2021
- 12 May 2021
- 4 May 2021
- 28 April 2021
Meetings
Australian Technical Advisory Group on Immunisation (ATAGI) – Meetings
ATAGI advice
COVID-19 vaccination – Provider resources
COVID-19 vaccination – Provider resources
COVID-19 vaccination – Patient resources
COVID-19 vaccination – Patient resources
Related committees and groups
Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 Working Group
View the purpose and membership of the Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 Working Group.
Contact
If your query is regarding COVID-19 vaccine eligibility, supply and demand or any other COVID 19 related query, further information can be found on the COVID-19 vaccines webpage.
Media enquiries should be directed to news@health.gov.au. Individual ATAGI members are not authorised to speak on behalf of ATAGI.
For all other enquiries please email enquiries@health.gov.au.